Anticancer Bioscience Announces CNY63m (~USD10m) Financing to Advance its Synthetic Lethal Platform and Pre-clinical Oncology Pipeline

09 Feb, 2021

Anticancer Bioscience Announces CNY63m (~USD10m) Financing to Advance its Synthetic Lethal Platform and Pre-clinical Oncology Pipeline
Photo by Startaê Team on Unsplash

Anticancer Bioscience announced that it has raised CNY63m (~USD10m) to advance its synthetic lethal platform and preclinical oncology pipeline.
The financing was led by a small syndicate of undisclosed, experienced Chinese angel investors.
ACB is an international private company, commercialising discoveries emerging from Chinas worldleading cancer research at the J. Michael Bishop Institute of Cancer Research.

Asia Biotechnology
Crunchbase icon

Content report

The following text will be sent to our editors: